Maxwell Biosciences

[Not Yet Scheduled]
Founded in 2016, Maxwell Biosciences is a preclinical drug platform company which develops biomimetic therapeutics – synthetic compounds that mimic and improve upon biomolecules. Inspired by nature, these low-molecular weight compounds are created by Maxwell’s exclusive first-in-class, CLAROMER™ brand drug platform and have been shown to be effective in destroying viruses, bacteria, fungi and some cancers, while safely avoiding healthy cells.
These drug candidates have been shown to be well-tolerated in human tissues in vitro, and in animal studies. The compounds imitate key components of the immune system, humanity’s greatest asset in fighting disease. Maxwell’s technology is protected by granted patents and is led by a world-class team of experienced life science executives.
Company Type:
Privately Funded Company
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
CLAROMERS™, biomimetic, low-molecular weight compounds that fight infectious pathogens.
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
We have a growing family of compounds that can be licensed